0QXX.LSE Molecular Partners AG

Healthcare Commercial Services & Supplies London Exchange
2.85 GBP
Close of Nov 3, 2026
2.56 3.94
Market cap
GBP 60.4M
P/E
0.8x
P/B
-
ROE
-91.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0QXX.LSE undervalued?

Graham number

The Graham number of Molecular Partners AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Molecular Partners AG fundamental analysis

No fundamental analysis for Molecular Partners AG yet.

Molecular Partners AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Molecular Partners AG

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) …

Full company profile